UCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria by Brunschwig, C, Lawrence, N, Taylor, D, Abay, E, Njoroge, M, Basarab, GS, Le Manach, C, Paquet, T, Cabrera, D, Nchinda, AT, de Kock, C, Wiesner, L, Denti, P, Waterson, D, Blasco, B, Leroy, D, Witty, MJ, Donini, C, Duffy, J, Wittlin, S, White, KL, Charman, SA, Jiménez-Díaz, MB, Angulo-Barturen, I, Herreros, E, Gamo, FJ, Rochford, R, Mancama, D, Coetzer, TL, van der Watt, ME, Reader, J, Birkholtz, L-M, Marsh, KC, Solapure, SM, Vanaerschot, M, Fidock, DA, Fish, PV, Siegl, P, Smith, DA, Wirjanata, G, Noviyanti, R, Price, RN, Marfurt, J, Silue, KD, Street, LJ, Chibale, K

The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance by Murithi, JM, Pascal, C, Bath, J, Boulenc, X, Gnädig, NF, Pasaje, CFA, Rubiano, K, Yeo, T, Mok, S, Klieber, S, Desert, P, Jiménez-Díaz, MB, Marfurt, J, Rouillier, M, Cherkaoui-Rbati, MH, Gobeau, N, Wittlin, S, Uhlemann, A-C, Price, R, Wirjanata, G, Noviyanti, R, Tumwebaze, P, Cooper, RA, Rosenthal, PJ, Sanz, LM, Gamo, FJ, Joseph, J, Singh, S, Bashyam, S, Augereau, JM, Giraud, E, Bozec, T, Vermat, T, Tuffal, G, Guillon, J-M, Menegotto, J, Sallé, L, Louit, G, Cabanis, M-J, Nicolas, MF, Doubovetzky, M, Merino, R, Bessila, N, Angulo-Barturen, I, Baud, D, Bebrevska, L, Escudié, F, Niles, JC, Blasco, B, Campbell, S